Comparative in Silico Docking  Studies of Hinokitiol with Sorafenib and Nilotinib against Proto-Oncogene Tyrosine-Protein Kinase(ABL1) and  Mitogen-activated Protein Kinase (MAPK) to Target Hepatocellular Carcinoma

Mohamed Zerein Fathima; T.S. Shanmugarajan; S. Satheesh Kumar; B.V.Venkata Nagarjuna Yadav

doi:10.5958/0974-360X.2017.00053.1

Research Journal of Pharmacy and Technology

ISSN

0974-360X (Online)
0974-3618 (Print)

Submit Article

Comparative in Silico Docking Studies of Hinokitiol with Sorafenib and Nilotinib against Proto-Oncogene Tyrosine-Protein Kinase(ABL1) and Mitogen-activated Protein Kinase (MAPK) to Target Hepatocellular Carcinoma

Author(s): Mohamed Zerein Fathima, T.S. Shanmugarajan, S. Satheesh Kumar, B.V.Venkata Nagarjuna Yadav

Email(s): shanmuga5@yahoo.com

DOI: 10.5958/0974-360X.2017.00053.1

Address: Mohamed Zerein Fathima*, T.S. Shanmugarajan, S. Satheesh Kumar, B.V.Venkata Nagarjuna Yadav
Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels University (VISTAS), Pallavaram-600117, Tamilnandu, India.
*Corresponding Author

Published In: Volume - 10, Issue - 1, Year - 2017

Keywords:

Cite this article:
Mohamed Zerein Fathima, T.S. Shanmugarajan, S. Satheesh Kumar, B.V.Venkata Nagarjuna Yadav. Comparative in Silico Docking Studies of Hinokitiol with Sorafenib and Nilotinib against Proto-Oncogene Tyrosine-Protein Kinase(ABL1) and Mitogen-activated Protein Kinase (MAPK) to Target Hepatocellular Carcinoma. Research J. Pharm. and Tech. 2017; 10(1): 257-262. doi: 10.5958/0974-360X.2017.00053.1

View PDF